Eloxx Pharmaceuticals

Treatment of Rare Genetic Diseases

Health Tech & Life Sciences
Public on NASDAQ on Apr, 2018<br>

Company Overview

Snapshot

Founded in September 2013, Eloxx Pharmaceuticals operates with 11–50 employees. The company has raised $98.5M across four funding rounds from 10 investors. In April 2018, Eloxx Pharmaceuticals became public on NASDAQ.

Business overview

Eloxx Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of compounds for rare genetic diseases. Its core technology leverages platform technologies to correct nonsense mutations and ribosomal mutations, addressing conditions such as cystic fibrosis, Duchenne muscular dystrophy, Usher syndrome, and Alport syndrome. The company operates within the Health Tech & Life Sciences sector, specifically in Pharmaceuticals, targeting patients with genetic disorders.

Strategic signal

In September 2023, Eloxx Pharmaceuticals announced a $2 million registered direct offering. This financing event provides capital to support ongoing research and development efforts, signaling continued investor confidence and enabling the company to advance its pipeline of treatments for rare genetic diseases.

Company Intelligence Q&A

What was a significant recent financial event for Eloxx Pharmaceuticals?
In September 2023, Eloxx Pharmaceuticals announced a $2 million registered direct offering priced at-the-market under Nasdaq rules.
What was a key development regarding ELX-02 in September 2023?
In September 2023, Eloxx Pharmaceuticals reported independent confirmation of positive biopsy results in all patients treated with ELX-02 in a Phase 2 clinical study for Alport Syndrome.
When did Eloxx Pharmaceuticals become a public company?
Eloxx Pharmaceuticals became public on NASDAQ in April 2018, following a reverse merger with Sevion Therapeutics Inc.
What was the outcome of the Phase 2 combination clinical trial of ELX-02 for Class 1 Cystic Fibrosis patients?
In September 2022, Eloxx Pharmaceuticals reported that the Phase 2 combination clinical trial of ELX-02 in Class 1 Cystic Fibrosis patients failed to meet its primary endpoint.
What strategic partnership did Eloxx Pharmaceuticals enter into in March 2024?
In March 2024, Eloxx Pharmaceuticals entered into an exclusive agreement with Almirall to license ZKN-013 for rare dermatological diseases.

External links